Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Small pilot trials in STEMI patients suggest ticagrelor monotherapy right after primary PCI may reduce bleeding without a clear rise in ischemic events, but the evidence is too…
Yes. A large randomized trial found that a pressure optimization protocol during primary PCI for STEMI improved reperfusion success compared with conventional rapid…
Yes. Primary aldosteronism is consistently linked to lower blood potassium levels, and the drop is larger in more severe or unilateral cases [1][2][6].
In-stent restenosis after vertebral artery ostial stenting occurs in about 13.5% to 37.2% of cases, depending on the study and follow-up duration.
About half of patients develop acute kidney injury after type A aortic dissection surgery, with higher risk in older patients, those with renal malperfusion, and longer bypass…
Immune interactions, particularly involving T cells and the communication between vascular smooth muscle cells and immune cells, play a significant role in driving tissue…
People with SDHD mutations are frequently associated with multifocal tumors, which can include multiple pheochromocytoma or paraganglioma sites.
GLP-1 receptor agonists reduce major adverse limb events (MALE) and cardiovascular risks in people with type 2 diabetes and peripheral artery disease, based on meta-analyses.
Yes, GLP-1 receptor agonists reduce major limb events in patients with type 2 diabetes and peripheral artery disease, with a 27% lower risk shown in a 2026 meta-analysis.
Yes, tirzepatide may reduce major adverse limb events and cardiovascular risks in people with PAD, but direct trial data are still limited.
Incretin analogues (GLP-1 RAs) reduce cardiovascular risk in PAD by improving walking distance, lowering inflammation, and decreasing heart attack and stroke events.
SGLT2 inhibitors may lower all-cause mortality in transthyretin cardiomyopathy, but evidence is mixed; one study shows benefit, another shows no mortality reduction when added to…
Yes, furosemide plus hypertonic saline is linked to lower increases in biomarkers like NT-proBNP, IL-6, and sST2 after a saline load in ADHF patients, though baseline reductions…
Yes, natriuresis-guided protocols increase weight loss in acute decompensated heart failure, with a meta-analysis showing about 0.45 kg more weight loss at 48 hours compared to…
Evidence is mixed: one meta-analysis found natriuresis-guided protocols shortened hospital stays by about 1 day, but another found no significant difference.
Yes, Xarelto (rivaroxaban) is FDA-approved for stroke prevention in nonvalvular atrial fibrillation, based on the ROCKET-AF trial showing it is noninferior to warfarin with a…
Yes, left atrial appendage closure (LAAC) causes significantly less non-procedural bleeding than NOACs in patients with nonvalvular atrial fibrillation, based on recent trials.
Yes, sex differences exist: women with NVAF-related stroke tend to have worse short-term outcomes, but after adjusting for age and other factors, their long-term mortality risk…
Yes, left atrial appendage occlusion (LAAO) is associated with lower all-cause mortality compared to warfarin in patients with nonvalvular atrial fibrillation, based on network…
A 2024 trial found that a sirolimus-eluting iron bioresorbable scaffold did not perform as well as standard metallic stents for treating coronary artery disease in patients with…
Yes, the sirolimus-eluting iron scaffold (IBS) showed higher late lumen loss than the everolimus-eluting stent at 2 years in the IRONMAN-II trial.
Researchers use mice and rats with diet-induced obesity, heart attacks, or specific genetic changes to study cardiometabolic diseases like heart failure and diabetes.
Researchers induce cardiometabolic disease in mice primarily by feeding them a high-fat diet, often combined with chemical treatments like VCD to mimic postmenopausal states.
Yes, the ALBI score can predict mortality risk after NSTEMI, with higher scores indicating a significantly higher risk of death.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.